home / stock / kpti / kpti news


KPTI News and Press, Karyopharm Therapeutics Inc. From 12/23/19

Stock Information

Company Name: Karyopharm Therapeutics Inc.
Stock Symbol: KPTI
Market: NASDAQ
Website: karyopharm.com

Menu

KPTI KPTI Quote KPTI Short KPTI News KPTI Articles KPTI Message Board
Get KPTI Alerts

News, Short Squeeze, Breakout and More Instantly...

KPTI - Karyopharm submits U.S. marketing application for Xpovio

Karyopharm Therapeutics (NASDAQ: KPTI ) has submitted a New Drug Application (NDA) to the FDA seeking accelerated approval for XPOVIO (selinexor), an oral Selective Inhibitor of Nuclear Export (SINE) compound, as a new treatment for patients with relapsed or refractory diffuse large B-Cell...

KPTI - Karyopharm Submits New Drug Application to U.S. FDA for XPOVIO® (selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NEWTON, Mass., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for XPOVIO®...

KPTI - Will Karyopharm's Stock Take Off in 2020?

2020 looks to be an important year for Karyopharm Therapeutics (NASDAQ: KPTI) . First, Karyopharm expects to share the results from its ongoing phase 3 clinical trial. It also should receive feedback from European regulators on an earlier pivotal trial in multiple myeloma -- a type of cancer....

KPTI - Karyopharm Presents XPOVIO® (Selinexor) and Eltanexor Data at the American Society of Hematology 2019 Annual Meeting

-- Once-Weekly Oral Selinexor in Combination with Weekly Kyprolis® and Low Dose Dexamethasone Demonstrates 71% Overall Response Rate, Including a Complete Response Rate of 21%, in Patients with Heavily Pretreated, Kyprolis-Naïve Multiple Myeloma -- -- All Oral Regimen o...

KPTI - Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or Refractory Multiple Myeloma at the American Society of Hematology 2019 Annual Meeting

-- All Oral Regimen of Once Weekly Selinexor in Combination with Daily Pomalyst ® and Low Dose Dexamethasone Demonstrates 56% Overall Response Rate in Pomalyst ® -Naïve and Revlimid ® -Relapsed or -Refractory Myeloma with Progression-Free Survival of 12.2 Months -- ...

KPTI - How To Find Top Momentum Stocks In Healthcare

The healthcare sector seems to be waking up over the past several weeks. Political uncertainty has been hurting healthcare stocks throughout the past year, but this uncertainty seems to be dissipating as the Presidential election approaches, which is being a major tailwind for the healthcare ...

KPTI - SKT, CLVS among premarket gainers

ASLAN Pharmaceuticals (NASDAQ: ASLN ) +85%  on positive ASLAN004 data. More news on: ASLAN Pharmaceuticals Limited, Akari Therapeutics, Plc, Evofem Biosciences, Inc., Stocks on the move, Read more ...

KPTI - KPTI, TECD among premarket gainers

Can-Fite BioPharma (NYSEMKT: CANF ) +51% . after 9M results . More news on: Can-Fite BioPharma Ltd., ASLAN Pharmaceuticals Limited, SORL Auto Parts, Inc., Stocks on the move, Read more ...

KPTI - Healthcare On The March

Healthcare Pulse Healthcare is at its all-time highs eclipsing the highs recorded a year earlier during the Oct-Nov 2018 period. Of course, if one looks at the broader market which has been recording such all-time highs since the summer of this year, it's understandable to shrug shoulders ...

KPTI - 4 RNA Therapy Stocks For A Biotech Portfolio

Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...

Previous 10 Next 10